Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
Quantum BioPharma announced its placement in a BioMedWire editorial highlighting its lead asset, Lucid-MS, a patented therapy for Multiple Sclerosis. The company states that Lucid-MS is preparing to move into Phase 2 clinical trials, targeting the myelin sheath to prevent and reverse disease-related degradation.
Key figures
- Drug Name
- Lucid-MS
- Phase Of Trial
- Phase 2
- Unbuzzd royalty cap
- $250 million
- Ms patient population
- 2.9 million
- Unbuzzd ownership percent
- 19.84%
- Unbuzzd royalty rate final
- 3%
- Unbuzzd royalty rate initial
- 7%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.